Orzeyful (Oveporexton) for Narcolepsy Type 1: Dosing and Safety
Orzeyful (oveporexton) is dosed at 2 mg followed by 5 mg daily (taken 3 hours apart) or 2 mg twice daily for adults with narcolepsy type 1, representing the first FDA-approved orexin receptor 2 agonist that directly addresses the underlying orexin deficiency in NT1. 1, 2
Recommended Dosing Regimens
Based on the pivotal phase 2 trial, the most effective dosing strategies are:
- 2 mg twice daily (dosed 3 hours apart): Demonstrated mean improvement of 23.5 minutes on Maintenance of Wakefulness Test and -13.8 point reduction in Epworth Sleepiness Scale 1
- 2 mg followed by 5 mg daily (dosed 3 hours apart): Showed mean improvement of 25.4 minutes on MWT and -12.8 point reduction in ESS 1
- Alternative regimen: 7 mg once daily also showed efficacy (15.0 minute MWT improvement, -11.3 ESS reduction) 1
The 2 mg twice daily and 2 mg/5 mg regimens are preferred as they also significantly reduced cataplexy frequency (weekly incidence of 3.14 and 2.48 episodes respectively vs 8.76 for placebo at week 8). 1
Critical Safety Information
Common Adverse Events (Expect These)
- Insomnia (48% of patients): Most cases resolve within 1 week of continued treatment 1
- Urinary urgency (33%) and urinary frequency (32%) 1
- Pollakiuria (55%) in related OX2R agonist trials 3
- Salivary hypersecretion (25%) 3
- Headache, blurred vision, hyperhidrosis 1, 3
Important Clinical Considerations
Pregnancy and Breastfeeding: Based on animal data, oveporexton may cause fetal harm. Human data are insufficient to determine risk. 1 This is a critical counseling point for women of childbearing age.
No hepatotoxicity observed: Unlike some other wake-promoting agents, oveporexton did not demonstrate hepatotoxic effects in clinical trials. 1
Controlled substance status: While oveporexton is not mentioned as a scheduled substance in available data (unlike modafinil which is Schedule IV), clinicians should verify current DEA scheduling.
Clinical Context and Treatment Algorithm
When to Use Oveporexton
Oveporexton should be considered as a first-line option for NT1 because it:
- Addresses the underlying orexin deficiency rather than just symptoms 4, 2
- Improves all core NT1 symptoms: excessive daytime sleepiness, cataplexy, and cognitive dysfunction 1, 5
- Demonstrates cognitive benefits including improved attention (PVT lapses), memory (CPAL errors), and executive function (ONB, IDSST-s) 5
Comparison to Guideline-Recommended Alternatives
The 2021 AASM guidelines provide STRONG recommendations for four medications in NT1 6:
- Modafinil
- Pitolisant (another orexin-enhancing agent, but a histamine H3 receptor inverse agonist)
- Sodium oxybate (FDA black box warning for CNS depression and respiratory depression; Schedule III controlled substance) 6
- Solriamfetol (Schedule IV controlled substance) 6
Oveporexton's advantage: It is the only approved therapy directly replacing deficient orexin signaling via selective OX2R agonism, potentially offering superior disease-modifying effects compared to symptomatic treatments. 4, 2
Practical Management Approach
Initiation Strategy
- Start with 2 mg twice daily (3 hours apart) or 2 mg/5 mg daily regimen
- Counsel patients about transient insomnia - emphasize that 48% experience this but most cases resolve within 1 week 1
- Warn about urinary symptoms - urgency and frequency affect approximately one-third of patients 1
Monitoring
- Week 1-2: Contact patient to assess insomnia tolerance and urinary symptoms
- Week 6-8: Assess efficacy using objective measures (MWT if available) or ESS scores
- Ongoing: Monitor for sustained cataplexy reduction and cognitive improvements 1, 5
Common Pitfalls to Avoid
- Don't discontinue prematurely for insomnia - most cases self-resolve within 1 week
- Don't overlook pregnancy planning - counsel women of childbearing age about potential fetal harm
- Don't expect immediate cataplexy control - significant reduction occurs by week 8 1
Evidence Quality Assessment
The approval is based on high-quality phase 2 data 1 with phase 3 trials completed and additional global studies ongoing. 2 The 8-week phase 2 trial demonstrated clinically meaningful improvements across all primary and secondary endpoints with adjusted p-values ≤0.001 for wakefulness measures. 1 Long-term efficacy and safety data beyond 8 weeks remain limited and require further evaluation. 7